BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Argus Health
Queensland Health
US Army
AstraZeneca
UBS
Fish and Richardson
Dow
Novartis
Fuji

Generated: January 18, 2018

DrugPatentWatch Database Preview

M.V.I.-12 (WITHOUT VITAMIN K) Drug Profile

« Back to Dashboard

Which patents cover M.v.i.-12 (without Vitamin K), and when can generic versions of M.v.i.-12 (without Vitamin K) launch?

M.v.i.-12 (without Vitamin K) is a drug marketed by Hospira and is included in one NDA.

The generic ingredient in M.V.I.-12 (WITHOUT VITAMIN K) is ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine hydrochloride; riboflavin 5'-phosphate sodium; thiamine hydrochloride; vitamin a; vitamin e. There are six drug master file entries for this compound. Additional details are available on the ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine hydrochloride; riboflavin 5'-phosphate sodium; thiamine hydrochloride; vitamin a; vitamin e profile page.
Summary for M.V.I.-12 (WITHOUT VITAMIN K)
You have an error in your SQL syntax; check the manual that corresponds to your MariaDB server version for the right syntax to use near 'SODIUM','THIAMINE HYDROCHLORIDE','VITAMIN A','VITAMIN E') AND hsdb_drugname IS N' at line 1
US Patents:0
Applicants:1
NDAs:1